Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Metastatic pancreatic ductal adenocarcinoma, drawn from the whole corpus: 80 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Resistance to RAS inhibitors emerges within months and the best partner drugs are unknown.
Nothing recorded yet.
Background: Drug resistance (primary and acquired). Also on OnCo: Resistance atlas · Lines of therapy.
Checkpoint inhibitors fail outside mismatch repair deficient disease because the tumour excludes T cells.
Most patients are too unwell for FOLFIRINOX-type regimens and trials under-represent them.
Cachexia and thrombosis kill many patients before the cancer itself is the limiting problem.
Late diagnosis: half of patients present with metastases and no screening test exists for the general population.
Nothing recorded yet.
Nothing recorded yet.
Background: CA 19-9. Also on OnCo: Symptoms and red flags · Early detection roadmap.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 21 changes by month →When this page itself was last checked or edited.
OS 13.
A milestone in how this cancer is treated.
Breakthrough Therapy designation, previously treated metastatic PDAC
Liposomal irinotecan in NALIRIFOX first-line metastatic pancreatic cancer
No overall survival benefit from adding devimistat to modified FOLFIRINOX.